Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.51 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173000 | 0.93 | CYSLTR1 (0.61) | GRM2CYSLTR1CYSLTR2CTSDMAPT | |
| SCHEMBL3158201 | 0.90 | GRM2 (0.51) | GRM2CYSLTR1CYSLTR2CTSDMAPT | |
| SCHEMBL3163164 | 0.89 | MAPT (0.57) | GRM2CYSLTR1MAPTCYP2C9CYP2C19 | |
| SCHEMBL3164272 | 0.85 | GRM2 (0.42) | GRM2CYSLTR1CYSLTR2CTSDMAPT | |
| SCHEMBL3163411 | 0.83 | GRM2 (0.53) | GRM2CYSLTR1CYSLTR2MAPTCYP2C9 | |
| SCHEMBL3164213 | 0.83 | CYSLTR1 (0.60) | GRM2CYSLTR1CYSLTR2CTSD | |
| SCHEMBL3167057 | 0.82 | CYSLTR1 (0.51) | GRM2CYSLTR1CYSLTR2CTSDMAPT | |
| SCHEMBL3178020 | 0.81 | CYSLTR1 (0.50) | GRM2CYSLTR1CYSLTR2CTSDMAPT | |
| SCHEMBL3166517 | 0.79 | CYSLTR1 (0.57) | GRM2CYSLTR1CYSLTR2CTSD | |
| SCHEMBL3158049 | 0.79 | GRM2 (0.57) | GRM2CYSLTR1MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858646-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858646-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858646-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| EP-1817300-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | ARRAY BIOPHARMA, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | ARRAY BIOPHARMA, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | ARRAY BIOPHARMA, INC. | 2008-04-24 | — | — | US | disclosed |
| EP-1817300-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057860-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | HTR7, UGT2B7, HK1 | GRM2 406/4885CYSLTR1 260/4885CYSLTR2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.